Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC. Chen LN, Lee ATM, Nagasaka M, Ou SI, et al. J Thorac Oncol 2024;19:380-384.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen LN, Lee ATM, Nagasaka M, Ou SI, et al. Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC. J Thorac Oncol 2024;19:380-384.
PMID: 38453326